Lichenoid variant of chronic cutaneous graft versus host reaction post blood transfusion: A rare event post blood transfusion

Ramakrishnaiah, P; Lakshman, Archana; Aradhya, Sacchidanand Sarvajnamurthy; Veerabhadrappa, Nataraja H

doi:10.4103/0019-5154.159667

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lichenoid Graft-vs.-Host-Disease Corticosteroids are the backbone the treatment of cutaneous lichenoid GVHD, but ∼30% need additional immunosuppressant such as cyclosporine. cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, pentostatin, or high-dose thalidomide and hydroxychloroquine (184). Another option for skin involvement might be phototherapy, while extracorporeal photochemotherapy may improve cutaneous as well as systemic involvement (184).…”

Section: Nail Lichen Planusmentioning

confidence: 99%

See 1 more Smart Citation

Lichen Planus

et al. 2021

View full text Add to dashboard Cite

Lichen planus (LP) is a T cell-mediated disease affecting the stratified squamous epithelia of the skin and/or mucus membrane. Histologically, the disease is characterized by a lichenoid inflammatory infiltrate and vacuolar degeneration of the basal layer of the epidermis. LP has three major subtypes: Cutaneous, mucosal and appendageal LP. Rarely, it may affect the nails in the absence of skin and/or mucosal changes. LP may also be induced by several drugs, typically anti-hypertensive medication or be associated with infections, particularly viral hepatitis. The diagnosis is based on the clinical presentation and characteristic histological findings. Although the disease is often self-limiting, the intractable pruritus and painful mucosal erosions result in significant morbidity. The current first-line treatment are topical and/or systemic corticosteroids. In addition, immunosuppressants may be used as corticosteroid-sparing agents. These, however are often not sufficient to control disease. Janus kinase inhibitors and biologics (anti-IL-12/23, anti-IL17) have emerged as novel future treatment options. Thus, one may expect a dramatic change of the treatment landscape of LP in the near future.

show abstract

Section: Nail Lichen Planusmentioning

confidence: 99%

“…cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, pentostatin, or high-dose thalidomide and hydroxychloroquine ( 184 ). Another option for skin involvement might be phototherapy, while extracorporeal photochemotherapy may improve cutaneous as well as systemic involvement ( 184 ).…”

Section: Managementmentioning

confidence: 99%